Financhill
Buy
52

INSM Quote, Financials, Valuation and Earnings

Last price:
$77.03
Seasonality move :
34.7%
Day range:
$75.23 - $78.18
52-week range:
$21.92 - $84.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
35.07x
P/B ratio:
49.33x
Volume:
992.9K
Avg. volume:
1.9M
1-year change:
202.37%
Market cap:
$14.1B
Revenue:
$363.7M
EPS (TTM):
-$5.59

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.54
ARDX
Ardelyx
$111.2M -$0.00 72.66% -33.34% $10.75
BAX
Baxter International
$2.7B $0.53 -27.96% 589.09% $40.04
BMRN
Biomarin Pharmaceutical
$711M $0.74 14.22% 109.92% $96.72
FOLD
Amicus Therapeutics
$147.9M $0.09 23.74% -81.83% $16.73
OCGN
Ocugen
$300K -$0.05 -100% -- $6.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
INSM
Insmed
$77.77 $95.54 $14.1B -- $0.00 0% 35.07x
ARDX
Ardelyx
$5.42 $10.75 $1.3B -- $0.00 0% 3.82x
BAX
Baxter International
$34.85 $40.04 $17.8B 167.20x $0.17 2.64% 1.39x
BMRN
Biomarin Pharmaceutical
$71.55 $96.72 $13.7B 32.52x $0.00 0% 4.97x
FOLD
Amicus Therapeutics
$9.12 $16.73 $2.8B -- $0.00 0% 5.25x
OCGN
Ocugen
$0.57 $6.75 $167.2M -- $0.00 0% 38.26x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
INSM
Insmed
79.45% 6.110 8.91% 4.99x
ARDX
Ardelyx
46.54% 1.635 12.5% 3.95x
BAX
Baxter International
65.34% 0.281 88.33% 0.54x
BMRN
Biomarin Pharmaceutical
9.52% 0.102 4.75% 2.96x
FOLD
Amicus Therapeutics
66.78% 0.258 13.85% 2.36x
OCGN
Ocugen
49.18% 4.395 12.22% 2.71x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M
ARDX
Ardelyx
$97.9M $8.1M -15.08% -24.57% 9.07% $9.2M
BAX
Baxter International
$959M -$1M -3.07% -8.24% -15.29% $351M
BMRN
Biomarin Pharmaceutical
$611.2M $161.4M 6.92% 8.09% 23% $165.3M
FOLD
Amicus Therapeutics
$134.9M $16M -10.23% -35.23% 13.29% -$4.2M
OCGN
Ocugen
-- -$13.8M -136.46% -171.04% -1811.52% -$10.4M

Insmed vs. Competitors

  • Which has Higher Returns INSM or ARDX?

    Ardelyx has a net margin of -225.53% compared to Insmed's net margin of 4%. Insmed's return on equity of -41989.34% beat Ardelyx's return on equity of -24.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    ARDX
    Ardelyx
    84.27% $0.02 $324.1M
  • What do Analysts Say About INSM or ARDX?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Ardelyx has an analysts' consensus of $10.75 which suggests that it could grow by 98.34%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    ARDX
    Ardelyx
    9 2 0
  • Is INSM or ARDX More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.739%.

  • Which is a Better Dividend Stock INSM or ARDX?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or ARDX?

    Insmed quarterly revenues are $104.4M, which are smaller than Ardelyx quarterly revenues of $116.1M. Insmed's net income of -$235.5M is lower than Ardelyx's net income of $4.6M. Notably, Insmed's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 3.82x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    ARDX
    Ardelyx
    3.82x -- $116.1M $4.6M
  • Which has Higher Returns INSM or BAX?

    Baxter International has a net margin of -225.53% compared to Insmed's net margin of -18.6%. Insmed's return on equity of -41989.34% beat Baxter International's return on equity of -8.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    BAX
    Baxter International
    34.84% -$1.00 $20.2B
  • What do Analysts Say About INSM or BAX?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Baxter International has an analysts' consensus of $40.04 which suggests that it could grow by 14.9%. Given that Insmed has higher upside potential than Baxter International, analysts believe Insmed is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    BAX
    Baxter International
    3 11 1
  • Is INSM or BAX More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.

  • Which is a Better Dividend Stock INSM or BAX?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.64% to investors and pays a quarterly dividend of $0.17 per share. Insmed pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BAX?

    Insmed quarterly revenues are $104.4M, which are smaller than Baxter International quarterly revenues of $2.8B. Insmed's net income of -$235.5M is higher than Baxter International's net income of -$512M. Notably, Insmed's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 1.39x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    BAX
    Baxter International
    1.39x 167.20x $2.8B -$512M
  • Which has Higher Returns INSM or BMRN?

    Biomarin Pharmaceutical has a net margin of -225.53% compared to Insmed's net margin of 16.72%. Insmed's return on equity of -41989.34% beat Biomarin Pharmaceutical's return on equity of 8.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    BMRN
    Biomarin Pharmaceutical
    81.78% $0.64 $6.3B
  • What do Analysts Say About INSM or BMRN?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.72 which suggests that it could grow by 35.18%. Given that Biomarin Pharmaceutical has higher upside potential than Insmed, analysts believe Biomarin Pharmaceutical is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    BMRN
    Biomarin Pharmaceutical
    16 6 0
  • Is INSM or BMRN More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

  • Which is a Better Dividend Stock INSM or BMRN?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BMRN?

    Insmed quarterly revenues are $104.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Insmed's net income of -$235.5M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Insmed's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 32.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 4.97x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    BMRN
    Biomarin Pharmaceutical
    4.97x 32.52x $747.3M $124.9M
  • Which has Higher Returns INSM or FOLD?

    Amicus Therapeutics has a net margin of -225.53% compared to Insmed's net margin of 9.85%. Insmed's return on equity of -41989.34% beat Amicus Therapeutics's return on equity of -35.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    FOLD
    Amicus Therapeutics
    90.09% $0.05 $584.2M
  • What do Analysts Say About INSM or FOLD?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Amicus Therapeutics has an analysts' consensus of $16.73 which suggests that it could grow by 83.41%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    FOLD
    Amicus Therapeutics
    8 3 0
  • Is INSM or FOLD More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.

  • Which is a Better Dividend Stock INSM or FOLD?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or FOLD?

    Insmed quarterly revenues are $104.4M, which are smaller than Amicus Therapeutics quarterly revenues of $149.7M. Insmed's net income of -$235.5M is lower than Amicus Therapeutics's net income of $14.7M. Notably, Insmed's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 5.25x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    FOLD
    Amicus Therapeutics
    5.25x -- $149.7M $14.7M
  • Which has Higher Returns INSM or OCGN?

    Ocugen has a net margin of -225.53% compared to Insmed's net margin of -1816.75%. Insmed's return on equity of -41989.34% beat Ocugen's return on equity of -171.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    74.96% -$1.32 $1.4B
    OCGN
    Ocugen
    -- -$0.05 $58.3M
  • What do Analysts Say About INSM or OCGN?

    Insmed has a consensus price target of $95.54, signalling upside risk potential of 22.86%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1078.83%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    12 0 0
    OCGN
    Ocugen
    2 0 0
  • Is INSM or OCGN More Risky?

    Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.

  • Which is a Better Dividend Stock INSM or OCGN?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or OCGN?

    Insmed quarterly revenues are $104.4M, which are larger than Ocugen quarterly revenues of $764K. Insmed's net income of -$235.5M is lower than Ocugen's net income of -$13.9M. Notably, Insmed's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 35.07x versus 38.26x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    35.07x -- $104.4M -$235.5M
    OCGN
    Ocugen
    38.26x -- $764K -$13.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock